Double filtration plasmapheresis (DFPP) was originally used for blood group incompatible renal transplantation, and is recently extended to remove various auto-antibodies in adult patients with immune-mediated diseases. But this technique has seldom been applied in children, much less studied on its efficiency in removing specific plasma components, and safety in children. We performed a prospective and observational study over one year on children undergoing DFPP for various critical renal indications. There were 24 sessions in six patients consisted of 1 male and 5 females, median age 11.5 years (range 8-13 years) and median weight 37.5 kg (range 26.5-58 kg). These patients were allocated into three groups (severe SLE, ANCA-associated vasculitis and C3 glomerulopathy) by different disease. DFPP was performed by using a plasma separator (Plasmaflow OP-08W) and plasma fractionator (EC-20W). All patients had received 2 plasma volumes in each treatment for 3-6 sessions in two consecutive weeks. The pre- and post-procedure plasma samples of pathogenic autoantibodies, IgG, IgA, IgM, fibrinogen, albumin, calcium, phosphate, potassium were analyzed. Complications during the hospital stay were recorded. The result of treatment showed that plasma pathogenic autoantibodies were decreased substantially by 79.03% and 89.78% in either severe SLE or ANCA-associated vasculitis patients after the third session and the last session, respectively. Over the course of successive DFPP sessions, all patients showed improved kidney function and extra-renal manifestations. Cumulative removal of serum IgG, IgA, IgM, C3, fibrinogen, and albumin at the end of last sessions were 54.44%, 46.57%, 79.54%, 44.52%, 71.59%, and 13.29% respectively. Removal of calcium, phosphate, potassium, magnesium and creatinine were not statistically significant. Furthermore, we observed lesser episodes (4.17%) of hypotension with fresh frozen plasma replacements as replacement fluid, and neither bleeding nor membrane anaphylaxis was reported from the treatment. This report shows the efficacy of DFPP is high in pediatric patients with systemic lupus erythematosus, antineutrophil cytoplasmic antibody vasculitis, and C3 glomerulopathy. IgG, IgA, IgM, albumin, and fibrinogen are removed by DFPP. IgG is suboptimally removed whereas IgA, IgM, and fibrinogen are substantially removed. Except for lesser episodes of hypotension, other adverse effects and abnormal bleeding were not found in our patients. Therefore, DFPP can be recommended to treat, as a safe adjunctive therapy, different abnormal immunoglobulins-associated disorders in children.